
Zerlasiran, a short interfering RNA (siRNA) agent, produces a prolonged and significant reduction in lipoprotein(a) [Lp(a)] levels in adults with elevated Lp(a), including those with atherosclerotic cardiovascular disease (ASCVD).


coremsg

The experimental siRNA agent led to prolonged Lp(a) reduction of more than 90%, extended data from the phase 1 trial show, supporting the move to phases 2 and 3 trials.

Extended Zerlasiran Data Show Sustained Lp(a) Reduction

extended-data-from-apollo-phase-1-trial-demonstrate-sustained-reduction-in-lipoprotein-a-with-zerlasiran-treatment


Extended Data from APOLLO Phase 1 Trial Demonstrate Sustained Reduction in Lipoprotein(a) with Zerlasiran Treatment
